Obstetric analgesia and anaesthesia in SARS-CoV-2-positive parturients across 10 maternity units in the north-west of England: a retrospective cohort study

Since the start of the COVID-19 pandemic, few studies have reported anaesthetic outcomes in parturients with SARS-CoV-2 infection. We reviewed the labour analgesic and anaesthetic interventions utilised in symptomatic and asymptomatic parturients who had a confirmed positive test for SARS-CoV-2 across 10 hospitals in the north-west of England between 1 April 2020 and 31 May 2021. Primary outcomes analysed included the analgesic/anaesthetic technique utilised for labour and caesarean birth. Secondary outcomes included a comparison of maternal characteristics, caesarean birth rate, maternal critical care admission rate along with adverse composite neonatal outcomes. A positive SARS-CoV-2 test was recorded in 836 parturients with 263 (31.4%) reported to have symptoms of COVID-19. Neuraxial labour analgesia was utilised in 104 (20.4%) of the 509 parturients who went on to have a vaginal birth. No differences in epidural analgesia rates were observed between symptomatic and asymptomatic parturients (OR 1.03, 95%CI 0.64–1.67; p = 0.90). The neuraxial anaesthesia rate in 310 parturients who underwent caesarean delivery was 94.2% (95%CI 90.6–96.0%). The rates of general anaesthesia were similar in symptomatic and asymptomatic parturients (6% vs. 5.7%; p = 0.52). Symptomatic parturients were more likely to be multiparous (OR 1.64, 95%CI 1.19–2.22; p = 0.002); of Asian ethnicity (OR 1.54, 1.04–2.28; p = 0.03); to deliver prematurely (OR 2.16, 95%CI 1.47–3.19; p = 0.001); have a higher caesarean birth rate (44.5% vs. 33.7%; OR 1.57, 95%CI 1.16–2.12; p = 0.008); and a higher critical care utilisation rate both pre- (8% vs. 0%, p = 0.001) and post-delivery (11% vs. 3.5%; OR 3.43, 95%CI 1.83–6.52; p = 0.001). Eight neonates tested positive for SARS-CoV-2 while no differences in adverse composite neonatal outcomes were observed between those born to symptomatic and asymptomatic mothers (25.8% vs. 23.8%; OR 1.11, 95%CI 0.78–1.57; p = 0.55). In women with COVID-19, non-neuraxial analgesic regimens were commonly utilised for labour while neuraxial anaesthesia was employed for the majority of caesarean births. Symptomatic women with COVID-19 are at increased risk of significant maternal morbidity including preterm birth, caesarean birth and peripartum critical care admission.     

米索前列醇用于正常足月妊娠计划分娩临床效果分析

目的:研究米索前列醇促宫颈成熟、诱发临产的效果及用药量。方法:将200例正常足月孕妇随机分为催产素组(对照组)100例和米索前列醇组(观察组)100例。结果:①引产有效率观察组明显高于对照组;②米索前列醇用药1天有效率为91％,用药量为100.54±25.27μg;2天有效率为97％,用药量为108.76±63.53μg;③孕妇产后出血及剖宫产率两组无显著差异;④羊水混浊发生率,观察组高于对照组差异有显著性;新生儿窒息率,两组相同,差异无显著性。结论:米索前列醇促宫颈成熟及诱发临产效果明显好于催产素,用于正常足月妊娠进行计划分娩是一种安全、有效、方便的方法,值得推广。     

The Effects of Na~+/Ca~(2+) exchange (NCX) on the Repolarization of Canine Ventricular Myocyte-Potential Arrhythmogenic Effect of NCX during a Mis-matched Repolarization and Relaxation Xiamen Zhongshan Hospital, Xiamen Medical College, Xiamen University

The Effects of Na~+/Ca~(2+) exchange (NCX) on the Repolarization of Canine Ventricular Myocyte-Potential Arrhythmogenic Effect of NCX during a Mis-matched Repolarization and Relaxation Xiamen Zhongshan Hospital, Xiamen Medical College, Xiamen University@巩燕$Visiting scholar of cardiac arrhythmia research institute,university hospital of Oklahoma!U.S.A @王焱 @BELA Szabo$Basic cardiac research laboratory,cardiac arrhythmia research institute,university hospital of Oklahoma!…     

膜型尿LH酶联免疫试剂监测排卵

应用膜型尿促黄体激素(LH)酶联免疫试剂,对48例不育症患者60个周期进行排卵监测。结果显示基础体温双相型并有血孕酮分泌增加(48.4±20.7nmol/L)的47个周期,尿LH显色均阳性;而基础体温单相型且无孕酮分泌增加(2.6±1.5nmol/L)的13个周期,尿LH显色均阴性。提示膜型尿LH酶联免疫试剂预测排卵无假阳性及假阴性。间隔12小时收集标本,按中位数统计法,尿LH显色程度与血LH浓度呈正相关(r=0.9887,P<0.001)。尿LH显示(±)距排卵时间为32.1±3.1小时,显色加深至(+)距排卵时间为16.9±2.6小时,两组差异有极显著意义(P<0.001);而尿LH显色(++)、(+++)距排卵时间与显色(+)组比较差异无显著意义(P>0.05)。表明一次检测到尿LH显色加深,即可推测排卵反应时间。与基础体温、宫颈评分、B型超声等比较,其预测排卵的价值更为可靠,而且操作简便快速,2分钟显示结果。监测结果还提示尿LH显色阳性的47个周期中,优势卵泡在起始显色的72小时内消失的41个周期为正常排卵,72小时后仍未消失的6个周期为未破裂卵泡黄素化。